Manufacturing News

Drug maker eyes void left by rival

Diabetes drug maker Guangzhou Zhongyi Pharmaceutical Company is hoping to capitalize on bad press rival GlaxoSmithKline got recently over safety issues surrounding its popular diabetes medicine, Avandia.

Guangzhou Zhongyi's product, Xiaoke Pills, a combination of traditional Chinese and Western medicine, targets local diabetes sufferers drawn to traditional medicines, said Zou Qi, the firm's marketing director.

Liu Zhilong, a doctor specializing in treating diabetes at Guangdong Hospital of Traditional Chinese Medicine, said "Traditional Chinese medicines are actually quite effective in treating the disease," said Liu.

Last month, sales of British pharmaceutical giant's diabetes drug Avandia, was banned by the European Medicines Agency over concerns it may increase heart attack risk. All medicines containing rosiglitazone, including Avandia, Avandamet and Avandaryl, remain available in the US market, but additional safety labeling has been put in place concerning usage.

Earlier this week, GlaxoSmithKline ceased all promotional marketing of the drug in China, but sales are still permitted.

Most Viewed in 24 Hours

Special

Start a Digital Twin Journey from Engineering Simulation

Accenture releases survey of digital transformation

CIMC Reduces Unplanned Downtime by 30% with Greater Operational Insight from ThingWorx

Ansys Simulation Speeding up Autonomous Vehicles

回到顶部
  • Tel : 0086-27-87592219
  • Email : service@e-works.net.cn
  • Add: 3B1 International Business Center, No. 18 Jinronggang Road (No.4), East Lake High-tech Development Zone, Wuhan, Hubei, PRC. 430223
  • ICP Business License: 鄂B2-20030029-9
  • Copyright © e-works All Rights Reserved